Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

PRINT: A Protein Bioconjugation Method with Exquisite N-terminal Specificity.

Sur S, Qiao Y, Fries A, O'Meally RN, Cole RN, Kinzler KW, Vogelstein B, Zhou S.

Sci Rep. 2015 Dec 17;5:18363. doi: 10.1038/srep18363.

2.

Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency.

Tsutsumi Y, Kihira T, Tsunoda S, Kanamori T, Nakagawa S, Mayumi T.

Br J Cancer. 1995 May;71(5):963-8.

3.

Chemical modification of natural human tumor necrosis factor-alpha with polyethylene glycol increases its anti-tumor potency.

Tsutsumi Y, Kihira T, Yamamoto S, Kubo K, Nakagawa S, Miyake M, Horisawa Y, Kanamori T, Ikegami H, Mayumi T.

Jpn J Cancer Res. 1994 Jan;85(1):9-12.

4.
5.

Enhanced antitumor potency of polyethylene glycolylated tumor necrosis factor-alpha: a novel polymer-conjugation technique with a reversible amino-protective reagent.

Tsunoda S, Ishikawa T, Yamamoto Y, Kamada H, Koizumi K, Matsui J, Tsutsumi Y, Hirano T, Mayumi T.

J Pharmacol Exp Ther. 1999 Jul;290(1):368-72.

PMID:
10381801
6.

Antitumor activity of tumor necrosis factor-alpha conjugated with polyvinylpyrrolidone on solid tumors in mice.

Kamada H, Tsutsumi Y, Yamamoto Y, Kihira T, Kaneda Y, Mu Y, Kodaira H, Tsunoda SI, Nakagawa S, Mayumi T.

Cancer Res. 2000 Nov 15;60(22):6416-20.

7.

Optimal site-specific PEGylation of mutant TNF-alpha improves its antitumor potency.

Yoshioka Y, Tsutsumi Y, Ikemizu S, Yamamoto Y, Shibata H, Nishibata T, Mukai Y, Okamoto T, Taniai M, Kawamura M, Abe Y, Nakagawa S, Nagata S, Yamagata Y, Mayumi T.

Biochem Biophys Res Commun. 2004 Mar 19;315(4):808-14.

PMID:
14985084
8.

Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window.

Shibata H, Yoshioka Y, Ikemizu S, Kobayashi K, Yamamoto Y, Mukai Y, Okamoto T, Taniai M, Kawamura M, Abe Y, Nakagawa S, Hayakawa T, Nagata S, Yamagata Y, Mayumi T, Kamada H, Tsutsumi Y.

Clin Cancer Res. 2004 Dec 15;10(24):8293-300.

9.

Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates.

Santi DV, Schneider EL, Reid R, Robinson L, Ashley GW.

Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6211-6. doi: 10.1073/pnas.1117147109. Epub 2012 Apr 2.

10.

PEGylated recombinant human tumor necrosis factor alpha: pharmacokinetics and anti-tumor effects.

Li YP, Pei YY, Zhou ZH, Zhang XY, Gu ZH, Ding J, Gao XJ, Zhu JH.

Biol Pharm Bull. 2001 Jun;24(6):666-70.

11.

High resolution crystal structure of a human tumor necrosis factor-alpha mutant with low systemic toxicity.

Cha SS, Kim JS, Cho HS, Shin NK, Jeong W, Shin HC, Kim YJ, Hahn JH, Oh BH.

J Biol Chem. 1998 Jan 23;273(4):2153-60.

12.

Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates.

Zhao RY, Wilhelm SD, Audette C, Jones G, Leece BA, Lazar AC, Goldmacher VS, Singh R, Kovtun Y, Widdison WC, Lambert JM, Chari RV.

J Med Chem. 2011 May 26;54(10):3606-23. doi: 10.1021/jm2002958. Epub 2011 May 4.

PMID:
21517041
13.

PEGylation alleviates the non-specific toxicities of Alpha-Momorcharin and preserves its antitumor efficacy in vivo.

Deng NH, Wang L, He QC, Zheng JC, Meng Y, Meng YF, Zhang CJ, Shen FB.

Drug Deliv. 2016;23(1):95-100. doi: 10.3109/10717544.2014.905652. Epub 2014 Apr 30.

PMID:
24786488
15.

Molecular design of conjugated tumor necrosis factor-alpha: synthesis and characteristics of polyvinyl pyrrolidone modified tumor necrosis factor-alpha.

Kamada H, Tsutsumi Y, Tsunoda S, Kihira T, Kaneda Y, Yamamoto Y, Nakagawa S, Horisawa Y, Mayumi T.

Biochem Biophys Res Commun. 1999 Apr 13;257(2):448-53.

PMID:
10198233
16.

Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.

Basu A, Yang K, Wang M, Liu S, Chintala R, Palm T, Zhao H, Peng P, Wu D, Zhang Z, Hua J, Hsieh MC, Zhou J, Petti G, Li X, Janjua A, Mendez M, Liu J, Longley C, Zhang Z, Mehlig M, Borowski V, Viswanathan M, Filpula D.

Bioconjug Chem. 2006 May-Jun;17(3):618-30.

PMID:
16704199
17.

Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity.

Yamamoto Y, Tsutsumi Y, Yoshioka Y, Nishibata T, Kobayashi K, Okamoto T, Mukai Y, Shimizu T, Nakagawa S, Nagata S, Mayumi T.

Nat Biotechnol. 2003 May;21(5):546-52. Epub 2003 Mar 31.

PMID:
12665803
18.

Magnetic polycarbonate microspheres for tumor-targeted delivery of tumor necrosis factor.

Hu B, Du HJ, Yan GP, Zhuo RX, Wu Y, Fan CL.

Drug Deliv. 2014 May;21(3):204-12. doi: 10.3109/10717544.2013.843609. Epub 2013 Oct 14.

PMID:
24117028
19.

In vivo efficacy of recombinant methioninase is enhanced by the combination of polyethylene glycol conjugation and pyridoxal 5'-phosphate supplementation.

Sun X, Yang Z, Li S, Tan Y, Zhang N, Wang X, Yagi S, Yoshioka T, Takimoto A, Mitsushima K, Suginaka A, Frenkel EP, Hoffman RM.

Cancer Res. 2003 Dec 1;63(23):8377-83.

20.

Pharmacokinetic, biodistribution, and biophysical profiles of TNF nanobodies conjugated to linear or branched poly(ethylene glycol).

Vugmeyster Y, Entrican CA, Joyce AP, Lawrence-Henderson RF, Leary BA, Mahoney CS, Patel HK, Raso SW, Olland SH, Hegen M, Xu X.

Bioconjug Chem. 2012 Jul 18;23(7):1452-62. doi: 10.1021/bc300066a. Epub 2012 Jun 25.

PMID:
22731748

Supplemental Content

Support Center